Mechanism of Action

RETA's triple-receptor engagement creates complementary metabolic effects through three distinct but overlapping signaling pathways. GIP receptor agonism potentiates glucose-dependent insulin secretion and influences adipose tissue lipid handling. Activation of the second incretin receptor suppresses glucagon secretion, slows gastric emptying, and modulates appetite-regulating circuits in the hypothalamus.

The glucagon receptor component, unique to the triple-agonist approach, stimulates hepatic energy expenditure through glycogenolysis and gluconeogenesis upregulation, fatty acid oxidation, and thermogenesis. Structural studies using cryo-EM have revealed the binding conformations at all three receptors, providing molecular-level insight into the peptide's poly-pharmacology.

Research Applications

• → Engineered to engage three metabolic receptors: the GIP receptor, a second incretin receptor, and the glucagon receptor
• → Cryo-EM structural studies have resolved the ligand binding conformations at all three target receptors
• → Receptor-pharmacology work characterizes relative agonist potency and signaling bias at each of the three receptors
• → Built on a GIP receptor agonist scaffold subsequently modified to introduce cross-reactivity at the other two receptors
• → Used as an analytical standard in LC-MS and HPLC characterization of multi-receptor peptide agonists

Analytical Validation

RETA is verified via LC-MS and HPLC analysis. Each lot is tested for identity, purity (≥99% target), and endotoxin levels. Full certificate of analysis is available upon request.